Skip Nav Destination
Issues
1 December 2010
-
Cover Image
Cover Image
Brain metastases of breast cancer are associated with significant morbidity and mortality. In their study, Lockman and colleagues quantified permeability, and paclitaxel and doxorubicin uptake in over 2000 experimental brain metastatic lesions from two model systems. The representative image shown on the cover is a multimodal image illustrating a single metastatic brain lesion which has 10 fold greater permeability compared to that of normal brain. Despite the increased permeability, drug accumulation only reached cytotoxic levels (>1000 ng/g) in a small subset of metastatic lesions, indicating that new brain-permeable drugs will be required. The picture was obtained by multichannel imaging of the eGFP MDA-MB-231Br lesion (green), indocyanine green within the vasculature (yellow), and 14C-AIB phosphorescence (red). For further details, please see Lockman and coworkers on page 5664 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Human Cancer Biology
Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion
Laura Mosca; Sonia Fabris; Marta Lionetti; Katia Todoerti; Luca Agnelli; Fortunato Morabito; Giovanna Cutrona; Adrian Andronache; Serena Matis; Francesco Ferrari; Massimo Gentile; Mauro Spriano; Vincenzo Callea; Gianluca Festini; Stefano Molica; Giorgio Lambertenghi Deliliers; Silvio Bicciato; Manlio Ferrarini; Antonino Neri
Foxo3a Suppression of Urothelial Cancer Invasiveness through Twist1, Y-Box–Binding Protein 1, and E-Cadherin Regulation
Masaki Shiota; YooHyun Song; Akira Yokomizo; Keijiro Kiyoshima; Yasuhiro Tada; Hiroshi Uchino; Takeshi Uchiumi; Junichi Inokuchi; Yoshinao Oda; Kentaro Kuroiwa; Katsunori Tatsugami; Seiji Naito
Cancer Therapy: Preclinical
Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman; Rajendar K. Mittapalli; Kunal S. Taskar; Vinay Rudraraju; Brunilde Gril; Kaci A. Bohn; Chris E. Adkins; Amanda Roberts; Helen R. Thorsheim; Julie A. Gaasch; Suyun Huang; Diane Palmieri; Patricia S. Steeg; Quentin R. Smith
Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma
Anna Dubrovska; Jimmy Elliott; Richard J. Salamone; Sungeun Kim; Lindsey J. Aimone; John R. Walker; James Watson; Maira Sauveur-Michel; Carlos Garcia-Echeverria; Charles Y. Cho; Venkateshwar A. Reddy; Peter G. Schultz
Highly Purified Eicosapentaenoic Acid as Free Fatty Acids Strongly Suppresses Polyps in ApcMin/+ Mice
Lucia Fini; Giulia Piazzi; Claudio Ceccarelli; Yahya Daoud; Andrea Belluzzi; Alessandra Munarini; Giulia Graziani; Vincenzo Fogliano; Michael Selgrad; Melissa Garcia; Antonio Gasbarrini; Robert M. Genta; C. Richard Boland; Luigi Ricciardiello
TRAIL-Induced Apoptosis Is Preferentially Mediated via TRAIL Receptor 1 in Pancreatic Carcinoma Cells and Profoundly Enhanced by XIAP Inhibitors
Dominic Stadel; Andrea Mohr; Caroline Ref; Marion MacFarlane; Shaoxia Zhou; Robin Humphreys; Max Bachem; Gerry Cohen; Peter Möller; Ralf M. Zwacka; Klaus-Michael Debatin; Simone Fulda
Imaging, Diagnosis, Prognosis
Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett's-Associated Esophageal Adenocarcinoma
Giang Huong Nguyen; Aaron J. Schetter; David B. Chou; Elise D. Bowman; Ronghua Zhao; Jason E. Hawkes; Ewy A. Mathé; Kensuke Kumamoto; Yiqiang Zhao; Anuradha Budhu; Nobutoshi Hagiwara; Xin Wei Wang; Masao Miyashita; Alan G. Casson; Curtis C. Harris
Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples
Vera L. Costa; Rui Henrique; Stine A. Danielsen; Sara Duarte-Pereira; Mette Eknaes; Rolf I. Skotheim; Ângelo Rodrigues; José S. Magalhães; Jorge Oliveira; Ragnhild A. Lothe; Manuel R. Teixeira; Carmen Jerónimo; Guro E. Lind
Cancer Therapy: Clinical
Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors
Michele Del Vecchio; Roberta Mortarini; Stefania Canova; Lorenza Di Guardo; Nicola Pimpinelli; Mario R. Sertoli; Davide Bedognetti; Paola Queirolo; Paola Morosini; Tania Perrone; Emilio Bajetta; Andrea Anichini
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas
Monica M. Mita; Matthew A. Spear; Lorrin K. Yee; Alain C. Mita; Elisabeth I. Heath; Kyriakos P. Papadopoulos; Kristine C. Federico; Steven D. Reich; Ofelia Romero; Lisa Malburg; MaryJo Pilat; G. Kenneth Lloyd; Saskia T.C. Neuteboom; Gillian Cropp; Edward Ashton; Patricia M. LoRusso
Predictive Biomarkers and Personalized Medicine
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.